Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration

Vaccine

Volumn 27, Issue 27, 2009, Pages 3561-3567

  Künzi, Valérie ^a   Klap, Jaco M ^b   Seiberling, Michael K ^c   Herzog, Christian ^a   Hartmann, Katharina ^a   Kürsteiner, Oliver ^a   Kompier, Ronald ^b   Grimaldi, Roberto ^a   Goudsmit, Jaap ^b  

^a Berna Biotech AG   (Switzerland)

^b CRUCELL HOLLAND BV   (Netherlands)

^c Swiss Pharma Contract Ltd   (Switzerland)

Author keywords

Influenza; Intradermal vaccination; Virosomes

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; VIROSOME VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG SAFETY; ECCHYMOSIS; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SIDE EFFECT; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; FEMALE; HUMANS; INFLUENZA VACCINES; MALE; MIDDLE AGED; SAFETY; VACCINATION; VACCINES, VIROSOME;

EID: 65649119364     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.062     Document Type: Article

References (36)

1. Brady M.T. Influenza virus infections in children. Seminar Pediatr Infect Dis 9 (1998) 92-102
2. Centers for Disease Control and Prevention. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR 2008; 57:1-60.
3. Couch R.B., Kasel J.A., Glezen W.P., Cate T.R., Six H.R., Taber L.H., et al. Influenza: its control in persons and populations. J Infect Dis 153 (1986) 431-440
4. Cox N.J., and Subbarao K. Influenza. Lancet 354 (1999) 1277-1282
5. Glezen W.P., Taber L.H., Frank A.L., Gruber W.C., and Piedra P.A. Influenza virus infections in infants. Pediatr Infect Dis J 16 (1997) 1065-1068
6. Gross P.A., Quinnan G.V., Rodstein M., LaMontagne J.R., Kaslow R.A., Saah A.J., et al. Association of influenza immunization with reduction in mortality in an elderly population. A prospective study. Arch Intern Med 148 (1988) 562-565
7. Nichol K.L., Margolis K.L., Wuorenma J., and von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331 (1994) 778-784
8. 2) epidemic. JAMA 253 (1985) 1136-1139
9. Cohen G.M., and Nettleman M.D. Economic impact of influenza vaccination in preschool children. Pediatrics 106 (2000) 973-976
10. Esposito S., Marchisio P., Bosis S., Lambertini L., Claut L., Faelli N., et al. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 24 (2006) 629-635
11. Navas E., Salleras L., Dominguez A., Ibanez D., Prat A., Sentis J., et al. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives. Vaccine 25 (2007) 3233-3239
12. Salleras L., Dominguez A., Pumarola T., Prat A., Marcos M.A., Garrido P., et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine 24 (2006) 6638-6642
13. Nichol K.L., Lind A., Margolis K.L., Murdoch M., McFadden R., Hauge M., et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 333 (1995) 889-893
14. Holland D., Booy R., De Looze F., Eizenberg P., McDonald J., Karrasch J., et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 198 (2008) 650-658
15. Janeway C.A.J., Travers P., Walport M., and Capra J.D. Immunobiology: the immune system in health and disease. 4th ed. (1999), Garland Publishing, New York
16. Redfield R.R., Innis B.L., Scott R.M., Cannon H.G., and Bancroft W.H. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 254 (1985) 3203-3206
17. Sabchareon A., Chantavanich P., Pasuralertsakul S., Pojjaroen-Anant C., Prarinyanupharb V., Attanath P., et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 17 (1998) 1001-1007
18. Pancharoen C., Mekmullica J., Thisyakorn U., Kasempimolporn S., Wilde H., and Herzog C. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin Infect Dis 41 (2005) 1537-1540
19. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351 (2004) 2286-2294
20. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 (2004) 2295-2301
21. Künzi V., Kürsteiner O., Lazar H., and Seiberling M. Intradermal administration of a virosomal influenza vaccine: a promising antigen sparing strategy. Options for the control of influenza VI (2008), International Medical Press p. 380-382
22. Auewarakul P., Kositanont U., Sornsathapornkul P., Tothong P., Kanyok R., and Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 25 (2007) 659-663
23. Belshe R.B., Newman F.K., Wilkins K., Graham I.L., Babusis E., Ewell M., et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25 (2007) 6755-6763
24. Moser C., Amacker M., Kammer A.R., Rasi S., Westerfeld N., and Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines 6 (2007) 711-721
25. Herzog C, Hartmann K, Künzi V, Kürsteiner O, Mischler R, Lazar H. Eleven years of Inflexal V. Vaccine; submitted for publication.
26. The European Agency for the Evaluation of Medicinal Products (EMEA). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96; 1997.
27. WHO. Recommended composition of influenza virus vaccines for use in the 2007-2008 influenza season. Wkly Epidemiol Rec 82 (2007) 69-74
28. Mischler R., and Metcalfe I.C. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 20 (2002) B17-B23
29. Nicholson K.G., Wood J.M., and Zambon M. Influenza. Lancet 362 (2003) 1733-1745
30. WHO. Influenza: Report by the WHO Secretariat for 111th Session of the WHO Executive Board, January 2003. Document EB111/10; 2003.
31. Heikkinen T., Booy R., Campins M., Finn A., Olcen P., Peltola H., et al. Should healthy children be vaccinated against influenza? A consensus report of the Summits of Independent European Vaccination Experts. Eur J Pediatr 165 (2006) 223-228
32. McIntosh K., and Lieu T. Is it time to give influenza vaccine to healthy infants?. N Engl J Med 342 (2000) 275-276
33. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 338 (1998) 1405-1412
34. Beyer W.E., Palache A.M., de Jong J.C., and Osterhaus A.D. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20 (2002) 1340-1353
35. Glenn G.M., and Kenney R.T. Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol 304 (2006) 247-268
36. Garg S., Hoelscher M., Belser J.A., Wang C., Jayashankar L., Guo Z., et al. Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice. Clin Vaccine Immunol 14 (2007) 926-928